Clinical studies of DELATESTRYL did not include sufficient numbers of subjects, aged 65 and older, to determine whether they respond differently from younger subjects. Testosterone replacement is not indicated in geriatric patients who have age-related hypogonadism only (“andropause”), because there is insufficient safety and efficacy information to support such use. Current studies do not assess whether testosterone use increases risks of prostate cancer , prostate hyperplasia , and cardiovascular disease in the geriatric population.
Other significant adverse effects of testosterone supplementation include acceleration of pre-existing prostate cancer growth in individuals who have undergone androgen deprivation; increased hematocrit , which can require venipuncture in order to treat; and, exacerbation of sleep apnea .  Adverse effects may also include minor side-effects such as acne and oily skin, as well as, significant hair loss and/or thinning of the hair, which may be prevented with 5-alpha reductase inhibitors ordinarily used for the treatment of benign prostatic hyperplasia , such as finasteride .  Exogenous testosterone may also cause suppression of spermatogenesis , leading to, in some cases, infertility.  It is recommended that physicians screen for prostate cancer with a digital rectal exam and prostate-specific antigen (PSA) level before starting therapy, and monitor PSA and hematocrit levels closely during therapy. 
Testosterone enanthate ( USAN , BAN ) (brand names Delatestryl , Testostroval , Testro LA , Andro LA , Durathate , Everone , Testrin , Andropository ), or testosterone heptanoate , is an androgen and anabolic steroid and a testosterone ester .    Along with testosterone cypionate and testosterone propionate , it is one of the most widely used testosterone esters.  Testosterone enanthate was first introduced in 1952.  Administered via intramuscular injection , it is the most widely used form of testosterone in androgen replacement therapy .